Literature DB >> 12095990

Fatty acid infusion selectively impairs insulin action on Akt1 and protein kinase C lambda /zeta but not on glycogen synthase kinase-3.

Young-Bum Kim1, Gerald I Shulman, Barbara B Kahn.   

Abstract

To determine the mechanism(s) for insulin resistance induced by fatty acids, we measured the ability of insulin to activate phosphoinositide 3-kinase (PI3K) and multiple distal pathways in rats. Following a 5-h infusion of lipid or glycerol (control), rats underwent a euglycemic hyperinsulinemic clamp. Insulin stimulated IRS-1-associated PI3K activity in muscle of glycerol-infused rats 2.4-fold but had no effect in lipid-infused rats. IRS-2- and phosphotyrosine-associated PI3K activity were increased 3.5- and 4.8-fold, respectively, by insulin in glycerol-infused rats but only 1.6- and 2.3-fold in lipid-infused rats. Insulin increased Akt1 activity 3.9-fold in glycerol-infused rats, and this was impaired 41% in lipid-infused rats. Insulin action on Akt2 and p70S6K were not impaired, whereas activation of protein kinase C lambda/zeta activity was reduced 47%. Insulin inhibited glycogen synthase kinase 3alpha (GSK-3alpha) activity by 30% and GSK-3beta activity by approximately 65% and increased protein phosphatase-1 activity by 40-47% in both glycerol- and lipid-infused rats. Insulin stimulated glycogen synthase activity 2.0-fold in glycerol-infused rats but only 1.4-fold in lipid-infused rats. Thus, 1) elevation of fatty acids differentially affects insulin action on pathways distal to PI3K, impairing activation of Akt1 and protein kinase C lambda/zeta and 2) insulin action on glycogen synthase can be regulated independent of effects on GSK-3 and protein phosphatase-1 activity in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12095990     DOI: 10.1074/jbc.M204710200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  28 in total

Review 1.  Nutritional approaches for managing obesity-associated metabolic diseases.

Authors:  Rachel Botchlett; Shih-Lung Woo; Mengyang Liu; Ya Pei; Xin Guo; Honggui Li; Chaodong Wu
Journal:  J Endocrinol       Date:  2017-04-11       Impact factor: 4.286

2.  Losartan increases muscle insulin delivery and rescues insulin's metabolic action during lipid infusion via microvascular recruitment.

Authors:  Nasui Wang; Weidong Chai; Lina Zhao; Lijian Tao; Wenhong Cao; Zhenqi Liu
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-01-08       Impact factor: 4.310

Review 3.  Pathophysiology of insulin resistance and steatosis in patients with chronic viral hepatitis.

Authors:  Metin Basaranoglu; Gökcen Basaranoglu
Journal:  World J Gastroenterol       Date:  2011-09-28       Impact factor: 5.742

4.  Hypomorphic mutation of PGC-1beta causes mitochondrial dysfunction and liver insulin resistance.

Authors:  Claudia R Vianna; Michael Huntgeburth; Roberto Coppari; Cheol Soo Choi; Jiandie Lin; Stefan Krauss; Giorgio Barbatelli; Iphigenia Tzameli; Young-Bum Kim; Saverio Cinti; Gerald I Shulman; Bruce M Spiegelman; Bradford B Lowell
Journal:  Cell Metab       Date:  2006-12       Impact factor: 27.287

5.  ROCK1 isoform-specific deletion reveals a role for diet-induced insulin resistance.

Authors:  Seung-Hwan Lee; Hu Huang; Kangduk Choi; Dae Ho Lee; Jianjian Shi; Tiemin Liu; Kwang Hoon Chun; Ji A Seo; Ines S Lima; Janice M Zabolotny; Lei Wei; Young-Bum Kim
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-12-10       Impact factor: 4.310

6.  AMP-activated protein kinase (AMPK)α2 plays a role in determining the cellular fate of glucose in insulin-resistant mouse skeletal muscle.

Authors:  R S Lee-Young; J S Bonner; W H Mayes; I Iwueke; B A Barrick; C M Hasenour; L Kang; D H Wasserman
Journal:  Diabetologia       Date:  2012-12-08       Impact factor: 10.122

7.  Maternal high-fat diet triggers lipotoxicity in the fetal livers of nonhuman primates.

Authors:  Carrie E McCurdy; Jacalyn M Bishop; Sarah M Williams; Bernadette E Grayson; M Susan Smith; Jacob E Friedman; Kevin L Grove
Journal:  J Clin Invest       Date:  2009-01-19       Impact factor: 14.808

8.  Rosiglitazone, an agonist of peroxisome-proliferator-activated receptor gamma (PPARgamma), decreases inhibitory serine phosphorylation of IRS1 in vitro and in vivo.

Authors:  Guoqiang Jiang; Qing Dallas-Yang; Subarna Biswas; Zhihua Li; Bei B Zhang
Journal:  Biochem J       Date:  2004-01-15       Impact factor: 3.857

9.  Targeted disruption of ROCK1 causes insulin resistance in vivo.

Authors:  Dae Ho Lee; Jianjian Shi; Nam Ho Jeoung; Min Seon Kim; Janice M Zabolotny; Sam W Lee; Morris F White; Lei Wei; Young-Bum Kim
Journal:  J Biol Chem       Date:  2009-03-10       Impact factor: 5.157

Review 10.  Modulation of insulin action.

Authors:  L Pirola; A M Johnston; E Van Obberghen
Journal:  Diabetologia       Date:  2004-01-13       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.